InVivoSIM anti-human NGF (Tanezumab Biosimilar)
Catalog #SIM0017
Clone:
Tanezumab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Tanezumab making it ideal for research use. This Tanezumab biosimilar reacts with human nerve growth factor (NGF), a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain neurons. NGF is essential for the development and phenotypic maintenance of neurons in the peripheral nervous system (PNS) and for the functional integrity of cholinergic neurons in the central nervous system (CNS). Tanezumab was developed against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs.Specifications
| Isotype | Human IgG2, Īŗ |
|---|---|
| Recommended Isotype Control(s) | InVivoPlus human IgG2 isotype control |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Human NGF |
| Reported Applications |
NGF neutralization ELISA |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
| Sterility | 0.2 Āµm filtration |
| Purification | Protein A |
| RRID | AB_2927533 |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |
Recommended Products
-
Recommended Isotype Control(s)
InVivoPlus human IgG2 isotype control
-
Recommended Dilution Buffer
InVivoPure pH 7.0 Dilution Buffer
{{block class="Bioxcell\ExtraTabs\Block\Catalog\Product\View\Citations" name="citations" template="Bioxcell_ExtraTabs::citations.phtml"}}